Acadia Pharmaceuticals (ACAD) Total Liabilities (2010 - 2026)
Acadia Pharmaceuticals (ACAD) posted quarterly Total Liabilities of $357.2 million for Q1 2026, down 2.71% year-over-year from $367.1 million in Q1 2025, and up 6.04% quarter-over-quarter from $336.8 million in Q4 2025.
Acadia Pharmaceuticals (ACAD) Total Liabilities (2010 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Total Liabilities history runs 17 years deep, the most recent figure standing at $357.2 million for Q1 2026.
- In Q1 2026, Total Liabilities fell 2.71% year-over-year to $357.2 million; the TTM figure through Mar 2026 stood at $357.2 million (down 2.71% YoY), while the FY2025 annual figure was $336.8 million, down 25.97% from the prior year.
- Total Liabilities for Q1 2026 stood at $357.2 million, up from $336.8 million in the prior quarter.
- The five-year high for Total Liabilities was $455.0 million in Q4 2024, with the low at $176.8 million in Q3 2022.
- The 5-year median for Total Liabilities is $336.8 million (2025), against an average of $315.2 million.
- The sharpest annual moves came in 2023 and 2025: Total Liabilities jumped 69.27% in 2023, then decreased 25.97% in 2025.
- Acadia Pharmaceuticals' Total Liabilities stood at $187.4 million in 2022, then surged by 69.27% to $317.2 million in 2023, then surged by 43.43% to $455.0 million in 2024, then declined by 25.97% to $336.8 million in 2025, then climbed by 6.04% to $357.2 million in 2026.
- Business Quant data shows ACAD's Total Liabilities at $357.2 million in Q1 2026, $336.8 million in Q4 2025, and $413.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Acadia Pharmaceuticals | 4.86 Bn | 3.90 Bn | 279.64 Mn | 436.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 436.29 Mn |
| Mar 31, 2026 | 357.16 Mn |
| Dec 31, 2025 | 336.81 Mn |
| Sep 30, 2025 | 413.50 Mn |
| Jun 30, 2025 | 403.17 Mn |
| Mar 31, 2025 | 367.13 Mn |
| Dec 31, 2024 | 454.96 Mn |
| Sep 30, 2024 | 399.69 Mn |
| Jun 30, 2024 | 397.40 Mn |
| Mar 31, 2024 | 391.06 Mn |
| Dec 31, 2023 | 317.20 Mn |
| Sep 30, 2023 | 270.37 Mn |
| Jun 30, 2023 | 246.98 Mn |
| Mar 31, 2023 | 281.05 Mn |
| Dec 31, 2022 | 187.40 Mn |
| Sep 30, 2022 | 176.81 Mn |
| Jun 30, 2022 | 177.92 Mn |
| Mar 31, 2022 | 179.45 Mn |
| Dec 31, 2021 | 159.23 Mn |
| Sep 30, 2021 | 150.72 Mn |